Skip to main content
A Singapore Government Agency Website How to identify
Official website links end with .gov.sg
Government agencies communicate via .gov.sg websites (e.g. go.gov.sg/open). Trusted websites
Secure websites use HTTPS
Look for a lock () or https:// as an added precaution. Share sensitive information only on official, secure websites.

Government officials will never ask you to transfer money or disclose bank log-in details over a phone call.

Call the 24/7 ScamShield Helpline at 1799 if you are unsure if something is a scam.

Agency for Care Effectiveness
Drug guidance

Pembrolizumab for treating resectable Stage II, IIIA, or IIIB (T3-4N2) non-small-cell lung cancer

Condition

Cancer

Respiratory

1 June 2026

Published on 17 Feb 2025
Last Updated on 01 Jun 2026

Guidance Recommendations

The Ministry of Health’s Drug Advisory Committee has not recommended pembrolizumab for inclusion on the MOH List of Subsidised Drugs, when used in combination with platinum-containing chemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment after surgery, for the treatment of patients with resectable Stage II, IIIA, or IIIB (T3-4N2) non-small-cell lung cancer. The decision was based on the unfavourable cost-effectiveness of pembrolizumab compared with nivolumab, and an unacceptable pricing proposal from the company.

Clinical indication, subsidy class and MediShield Life claims eligibility for pembrolizumab are provided in the Annex.

Pembrolizumab for treating resectable Stage II, IIIA, or IIIB (T3-4N2) non-small-cell lung cancer (1 Jun 2026) [PDF, 218 KB]

PES Pembrolizumab for treating non-small-cell lung cancer before and after lung surgery (4 Jun 2025) [PDF, 61 KB]

Back to top